Europe – Sanofi gains EU nod to market recombinant flu vaccine

  • The European Commission has granted a marketing authorization for Sanofi’s (SNY +1.3%) Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine.
  • The company says that Supemtek contains three times more antigen than both egg-based and cell-based standard-dose vaccines, thus provide improved protection against influenza…